EVOKE-02

Loading viewer...

report

Format: PDF report

This report details the EVOKE-02 study, a Phase 2 clinical trial evaluating Sacituzumab Govitecan combinations for treating advanced NSCLC without actionable genomic alterations.

Browse all reports →

Related tags

Your message matters.

Let us design a presentation that delivers.

Lets get started

More from Gilead Biosciences

View all →

brochure

brochure

Similar reports from other companies

Browse all →

report

1st Source Corporation

report

Berg Insight